ECOG Performance Status in T-DM1 and Enhertu Trials for HER2-Positive Metastatic Breast Cancer
Patients enrolled in pivotal trials of both T-DM1 and Enhertu (trastuzumab deruxtecan) for HER2-positive metastatic breast cancer were required to have an ECOG performance status of 0 or 1.
Trial Eligibility Criteria
T-DM1 Studies
According to the 2022 ASCO guidelines, the EMILIA trial (second-line T-DM1 vs lapatinib plus capecitabine) and the MARIANNE trial (first-line T-DM1 with or without pertuzumab vs trastuzumab plus taxane) both required ECOG PS 0 or 1 as an inclusion criterion 11. This represents patients who are fully ambulatory (ECOG 0) or restricted in physically strenuous activity but ambulatory and able to carry out light work (ECOG 1).
Enhertu (Trastuzumab Deruxtecan) Studies
The FDA label and clinical trial data consistently show that Enhertu trials also required ECOG PS 0 or 1 2:
- DESTINY-Breast03 (Enhertu vs T-DM1, second-line): 63% had ECOG 0 and 37% had ECOG 1 at baseline
- DESTINY-Breast02 (Enhertu vs physician's choice, post-T-DM1): 57% had ECOG 0 and 42% had ECOG 1 at baseline 2
- DESTINY-Breast01 (single-arm Enhertu study): 55% had ECOG 0 and 44% had ECOG 1; notably, patients with ECOG >1 were explicitly excluded 2
The NCCN 2026 guidelines confirm these eligibility criteria across multiple Enhertu trials, consistently documenting ECOG PS 0-1 as the inclusion standard 3333.
Real-World Evidence
Recent real-world studies show broader application in clinical practice. One 2026 cohort study reported that 16.7% of patients treated with T-DXd had ECOG ≥2, demonstrating that real-world use extends beyond trial eligibility criteria 4. However, this represents off-label use in more debilitated patients and does not reflect the evidence base supporting these therapies.
Clinical Implications
The evidence supporting both T-DM1 and Enhertu is limited to patients with good functional status (ECOG 0-1). Patients with ECOG PS ≥2 were systematically excluded from registration trials, meaning efficacy and safety data in this population are lacking. When considering these therapies for patients with poorer performance status, clinicians must recognize they are extrapolating beyond the evidence base, and outcomes may differ substantially from trial results.
The consistency of ECOG 0-1 requirements across all major HER2-directed antibody-drug conjugate trials reflects both the need for patients to tolerate intensive therapy and the desire to minimize confounding from poor baseline functional status when assessing treatment efficacy 112567.